Evidence map›Paper›PMID 30057540›Full record

ArticleCase reports in oncology

Usefulness of

Tomoyuki Nakano, Kaoru Tamura, Yoji Tanaka, Motoki Inaji, Shihori Hayashi, Daisuke Kobayashi, Tadashi Nariai, Jun Toyohara, Kenji Ishii, Taketoshi Maehara

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tomoyuki NakanoDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Kaoru TamuraDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Yoji TanakaDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Motoki InajiDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Shihori HayashiDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Daisuke KobayashiDepartment of Human Pathology, Tokyo Medical and Dental University, Tokyo, Japan.
Tadashi NariaiDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Jun ToyoharaResearch Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Kenji IshiiResearch Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Taketoshi MaeharaDepartment of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan.
Tokyo Medical and Dental University · JPTokyo Metropolitan Institute of Gerontology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently developed molecular targeted therapies such as bevacizumab (BEV; Avastin) therapy have therapeutic efficacy for glioblastoma. However, it is difficult to distinguish between a tumor response and nonenhancing tumor progression with conventional magnetic resonance imaging (MRI) after BEV administration. Here we present a recurrent glioblastoma case in which

Indexed as

11C-methionine positron emission tomographyBevacizumabGlioblastomaRecurrenceVascular endothelial growth factor

Identifiers

PMID30057540
PMCPMC6062727
OpenAlexW2810670668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.